CERA + darbepoetin alfa

This is a combination therapy of **continuous erythropoietin receptor activator (CERA)** and **darbepoetin alfa**, both of which are erythropoiesis-stimulating agents (ESAs). These agents function as synthetic forms of erythropoietin, stimulating erythropoiesis by binding to and activating the erythropoietin receptor on erythroid progenitor cells in the bone marrow. This results in increased red blood cell production, correction of anemia, and maintenance of hemoglobin levels, especially in patients with chronic kidney disease (CKD)[1][2]. CERA is a pegylated, long-acting ESA (methoxy polyethylene glycol-epoetin beta) with an extended half-life compared to other ESAs, allowing for less frequent dosing (every 2-4 weeks)[2]. Darbepoetin alfa is a hyperglycosylated ESA, also with an extended half-life compared to epoetin alfa/beta, usually administered weekly or biweekly[2][5]. Both drugs are primarily indicated for the treatment of anemia due to CKD. This combination refers to research studies directly comparing the safety and efficacy of these agents; there is no fixed-dose combination product but rather head-to-head use in clinical studies[1][2].

Brand names

AranespMircera

Other names

darbepoetin alfa + CERAdarbepoetin alfa + Continuous Erythropoietin Receptor Activatordarbepoetin alfa + CERA-Ospedale Regionale di Locarno-anemia (chronic kidney disease)